Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Profund Advisors LLC Purchases 4,352 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)
11:36am, Monday, 06'th Apr 2020
Profund Advisors LLC raised its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 21.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 24,809 shares of the
Amicus Therapeutics, Inc. (NASDAQ:FOLD) COO Sells $136,377.27 in Stock
09:58am, Monday, 06'th Apr 2020
Amicus Therapeutics, Inc. (NASDAQ:FOLD) COO Bradley L. Campbell sold 15,003 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $9.
Bank of New York Mellon Corp Has $21.97 Million Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)
09:58am, Monday, 06'th Apr 2020
Bank of New York Mellon Corp lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 3.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 2,255,08
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by AQR Capital Management LLC
09:14am, Monday, 06'th Apr 2020
AQR Capital Management LLC decreased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 12.5% during the 4th quarter, according to its most recent 13F filing with the Securities and
John F. Crowley Sells 9,755 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock
11:28am, Sunday, 05'th Apr 2020
Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 9,755 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $9.08, for a total val
Coronavirus Roundtable - Strains And Hopes In The Healthcare Sector
11:30am, Saturday, 04'th Apr 2020
The healthcare sector is on the front lines of treating, preventing, and ultimately solving the coronavirus issues. We discuss with our panelists how the sector
Amicus Therapeutics Company Profile: Stock Performance & Earnings | PitchBook
06:02pm, Friday, 03'rd Apr 2020
Information on stock, financials, earnings, subsidiaries, investors, and executives for Amicus Therapeutics. Use the PitchBook Platform to explore the full profile.
Makers of Keep Protocol Raise $7.7M to Bring Trustless BTC to DeFi
05:00pm, Thursday, 02'nd Apr 2020
Thesis has closed a $7.7 million deal by selling its KEEP tokens to some of crypto’s top investors. Its TBTC project could get more bitcoin into DeFi.
Amicus Therapeutics (NASDAQ:FOLD) Downgraded by BidaskClub
09:22am, Thursday, 02'nd Apr 2020
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Thursday, BidAskClub reports. A number of other r
Amicus Therapeutics (FOLD) Up 1.1% Since Last Earnings Report: Can It Continue?
03:30pm, Wednesday, 01'st Apr 2020
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amicus Therapeutics (FOLD) Up 1.1% Since Last Earnings Report: Can It Continue?
03:30pm, Wednesday, 01'st Apr 2020
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks: Brokerages Expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to Post -$0.29 Earnings Per Share
09:10am, Wednesday, 01'st Apr 2020
Brokerages forecast that Amicus Therapeutics, Inc. (NASDAQ:FOLD) will report ($0.29) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have issued
Amicus Therapeutics (FOLD) Up 1.1% Since Last Earnings Report: Can It Continue?
12:00am, Wednesday, 01'st Apr 2020XBI: Biotech ETF Expected To Outperform During And After The Coronavirus Pandemic
02:32pm, Tuesday, 31'st Mar 2020
S&P Biotech ETF (XBI) slumped -20% year-to-date, in-line with the S&P 500, due to the unrelenting coronavirus pandemic,. Heavy exposure to small caps contribute
Zacks: Analysts Expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) Will Announce Quarterly Sales of $57.21 Million
05:58am, Tuesday, 31'st Mar 2020
Equities research analysts expect Amicus Therapeutics, Inc. (NASDAQ:FOLD) to announce $57.21 million in sales for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for A
